Vivimed announces the receipt of Government of India (Director General of Health Services ) approval to Manufacture and market Favipiravir Tablet 200 mg & 400 mg for Indian Market

Hyderabad, India, May 10, 2021 — Vivimed Labs Limited (“Vivimed” or the Company), a niche Specialty Chemicals and Pharmaceuticals company, announced today, the receipt of Government of India (Director General of Health Services ) approval to Manufacture and market Favipiravir Tablet 200 mg & 400 mg under Vivimed’s own brand name “Favulous” across India. It is used for the treatment of mild to moderate cases of Covid-19 . Favipiravir is one of the leading oral anti-viral treatment approved in various countries for the potential treatment of patients with mild to moderate Covid-19 disease.
 
Favipiravir registered highest sales in the month of April 2021. To register as top pharma brand in the domestic market(Fabiflu:Glenmark:762 Crores)
 
Commenting on the launch, Ramesh Krishnamurthy, CEO of Vivimed Labs Ltd said, “With huge spike in Covid19 cases being reported daily in India, there is an urgent need to provide more treatment options to healthcare professionals. We are launching “Favulous” at a competitive price to make the drug accessible to more and more patients thereby ensuring good health and reducing their financial burden. This is in line with Vivimed’s commitment to be at forefront in India’s fight against Covid-19.”
 
The company will work closely with the various governments and medical community to ensure availability of “Favulous” to patients across the Country.
 
For further information on Vivimed, visit www.vivimedlabs.com

To read more Press Release articles, click here.